Novavax, Inc.

NVAX

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$8.655

−$0.285 · -3.19%

Aug 24, 11:18 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

55/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Deep Value

Momentum

Neutral

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $8.655

$8.26$8.88

52-week range

Current $8.655

$6.20$11.97

Open: $8.88
Previous close: $8.94
Volume: 2.53M
Market cap: 1.42B USD
50-day average: $8.4618; +2.28% above average
200-day average: $8.4367; +2.59% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.1B USD
EV / EBITDA: 2.23×
Earnings yield: 40.45%
Free cash flow yield: -22.98%

Profitability & efficiency

Return on equity: -344.65%
Return on assets: 37.42%
Return on invested capital: 78.00%

Financial health

Current ratio: 2.13×

Earnings

Latest fiscal-year EPS: 2.54; FY2025
Latest fiscal-year revenue: 1.12B USD; FY2025 · +64.69% year over year
Next fiscal-year EPS consensus: -0.729; FY2026 · 8 analysts
Next fiscal-year revenue consensus: 363.12M USD; FY2026 · 7 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

23 ratings

Strong buy00%

Buy1774%

Hold313%

Sell313%

Strong sell00%

Recent analyst actions

6 institutions

NVAX news

schaeffersresearch.comAug 19, 2026

Gold Mining, Drug Stocks Breaking Out Today

A third drug stock making plenty of progress in today's trading

Read source

zacks.comAug 7, 2026

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.

Read source

marketbeat.comAug 7, 2026

Novavax Q2 Earnings Call Highlights

Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued…

Read source

seekingalpha.comAug 6, 2026

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Read source

zacks.comAug 6, 2026

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to earnings of $0.62 per share a year ago.

Read source